SkinBioTherapeutics (LON:SBTX) Trading Up 6.2% – What’s Next?

SkinBioTherapeutics plc (LON:SBTX) was up 6.2% on Friday . The stock traded as high as GBX 9 and last traded at GBX 6.90. Approximately 2,144,433 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 4,275,483 shares. The stock had previously closed at GBX 6.50.

SkinBioTherapeutics Trading Up 6.2%

The company has a market capitalization of £17.88 million, a P/E ratio of -22.26 and a beta of 0.47. The stock’s 50 day moving average is GBX 9.60 and its 200-day moving average is GBX 12.55. The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01.

SkinBioTherapeutics (LON:SBTX) last released its quarterly earnings results on Monday, June 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.The company had revenue of GBX 217 million during the quarter.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.